A case of Rowell syndrome with excellent improvement following anifrolumab

An impressive case of Rowell syndrome with extensive mucosal involvement successfully treated with anifrolumab

“…Our case is unique because of the severe mucosal involvement at diagnosis. Given the patient’s excellent response to anifrolumab, we echo Shope et al 4 recommendation of anifrolumab in refractory cutaneous lupus, especially when significant mucosal lesions are present. Further studies are warranted to examine the efficacy of anifrolumab for other cutaneous lupus variants.…”

“…For example, Sigh et al 3 introduced rituximab as an effective treatment for refractory RS. We also greatly appreciate Shope et al 4 reporting a uncommon patient with RS, without mucosal lesions, showing excellent response to anifrolumab, a human monoclonal antibody to the type 1 interferon receptor, after failing first-line treatments and rituximab. 4 , 5 To our knowledge, this is the only case reported in the literature of successfully using anifrolumab for RS.…”

“…We also greatly appreciate Shope et al 4 reporting a uncommon patient with RS, without mucosal lesions, showing excellent response to anifrolumab, a human monoclonal antibody to the type 1 interferon receptor, after failing first-line treatments and rituximab. 4 , 5 To our knowledge, this is the only case reported in the literature of successfully using anifrolumab for RS. Herein, we highlight another patient with RS with severe mucocutaneous lesions that resolved with anifrolumab after failing standard first-line treatments and belimumab.…”

Targetoid‐like lesions and chilblain‐like erythema manifested on hands and feet: A case of Rowell syndrome from China

“…The precise etiopathogenesis of RS remains unclear; however, it is believed that it may be triggered by drug, infection, ultraviolet exposure, cigarette smoking, and psychological stress 4 . Corticosteroids, hydroxychloroquine, immunosuppression, and biologic treatments (such as anifrolumab) are among the therapeutic options for RS 5 . SLE is a chronic autoimmune‐mediated inflammatory disorder with multisystem and multiorgan involvement.…”

“… 4 Corticosteroids, hydroxychloroquine, immunosuppression, and biologic treatments (such as anifrolumab) are among the therapeutic options for RS. 5 SLE is a chronic autoimmune‐mediated inflammatory disorder with multisystem and multiorgan involvement. Frostbite‐like lesions in the extremities are frequently significant clinical symptoms of vasculitis in SLE, but the limbs do not typically develop multiform erythematous skin lesions.…”